Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07444619 · ClinicalTrials.gov registry record · Phase 1

A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas

A Phase 1 study, sponsored by M.D. Anderson Cancer Center.

Not yet
Registry status
Phase 1
Development phase
18
Enrollment target

NCT07444619: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.

NCT07444619 is a Phase 1 study that has not yet begun recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT07444619, a Phase 1 study, has not yet begun recruiting, sponsored by M.D. Anderson Cancer Center.

NOT YET RECRUITING
Registry status
Phase 1
Development phase
18 participants
Enrollment target

Study Summary

The goal of this study is to build on the experience of the SAINT trial by evaluating the safety and efficacy of the addition of pazopanib to their published chemotherapy regimen.

Primary Outcome

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Interventions

  • DRUG Nivolumab
  • DRUG Ipilimumab
  • DRUG Pazopanib
  • DRUG Trabectedin

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2026-08-31
Est. Completion 2033-12-31
Phase Phase 1
M.D. Anderson Cancer Center

2,692 total trials

What is known before NCT07444619 opens enrollment

NCT07444619 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).

The record links to 0 conditions, and to 4 interventions - of which Nivolumab is the first listed.

NCT07444619 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07444619 about?

NCT07444619 is a clinical study titled "A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas". The goal of this study is to build on the experience of the SAINT trial by evaluating the safety and efficacy of the addition of pazopanib to their published chemotherapy regimen.

What is the current status of trial NCT07444619?

This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2026-08-31. Estimated completion is 2033-12-31.

What interventions are being tested in trial NCT07444619?

The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Pazopanib (DRUG), Trabectedin (DRUG).

Who is sponsoring clinical trial NCT07444619?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Learn More About Clinical Trials

How this trial's enrollment target compares

Where NCT07444619's enrollment target sits among peer trials

18 1720th of 2000 higher than 216 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01245179 · 18 participants · Phase 1

    Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

  • NCT01999361 · 18 participants · NA

    Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

  • NCT02359825 · 18 participants · Phase 1

    Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function

  • NCT02870244 · 18 participants · Phase 1

    Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07444619, the US trial registry maintained by the National Library of Medicine. NCT07444619 (small enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.